Results 321 to 330 of about 59,693 (345)

Spironolactone in the treatment of hirsutism

Archives of Gynecology, 1987
Spironolactone was used in 90 hirsute women because of its antiandrogenic effect. The drug was administered twice daily from the 4th to the 22nd day of six cycles (total dosage was 200 mg per day). The results suggest that spironolactone is suitable for the treatment of hirsutism.
Recai Pabuçcu, Atilla Köksal, Cemalettin Akyürek   +2 more
openaire   +3 more sources

Spironolactone in dermatology: uses in acne and beyond

Clincal and Experimental Dermatology, 2020
Spironolactone is a synthetic aldosterone receptor antagonist, with a role off‐label in various dermatological conditions. Its antiandrogenic properties make it suitable for diseases in which excess androgen production results in unwanted and ...
T. Searle, F. Al-Niaimi, F. R. Ali
semanticscholar   +1 more source

Spironolactone in dermatologic therapy

Journal of the American Academy of Dermatology, 1991
In the treatment of androgen-mediated skin disorders spironolactone provides a valuable therapeutic option. This article reviews the use of spironolactone as an antiandrogen in dermatologic therapy. The endocrinologic effects, pharmacology, dermatologic uses, and side effects are discussed, and guidelines for its use are provided.
openaire   +2 more sources

Comparison of spironolactone and spironolactone plus finasteride in the treatment of hirsutism [PDF]

Fertility and Sterility, 2002
Objective: To compare the clinical efficacy and safety of the combination of spironolactone (100 mg/day) plus finasteride (5 mg/day) and spironolactone (100 mg/day) alone in the treatment of hirsutism. Patients and measurements: Sixty-five hirsute women were randomly assigned to one of these two treatment groups.
Fahrettin Kelestimur, K.ürşad Ünlühızarcı, Hatice Everest, Fahri Bayram   +3 more
openaire   +1 more source

Spironolactone and plasma cortisol

Clinical Pharmacology & Therapeutics, 1973
Spironolactone has been shown to interfere with the determination of corticosteroids in plasma and urine. In the present study the fluorimetric method of Mattingly was used to determine how rapidly the spurious elevation of plasma cortisol develops after spironolactone administration and to define the rate of disappearance of the artifact from plasma ...
Chakhavarthy Kannan, Juliet S. Dumlao, Marion H. Brooks, Thomas Krauss   +3 more
openaire   +3 more sources

Pharmacokinetics of spironolactone in man

Naunyn-Schmiedeberg's Archives of Pharmacology, 1976
Five healthy male volunteers received 500 mg Aldactone orally together 100 muCi 3H-20-21-spironolactone; one elderly patient received 1 mCi 3H-spironolactone without additional 'cold' drug. For 6 days the disposition kinetics of the drug were studied in plasma, urine and feces. The tritium concentrations in plasma reached a peak between 25-40 min after
G. Luszpinski, U. Abshagen, H. Rennekamp
openaire   +3 more sources

Adverse Reactions to Spironolactone

JAMA: The Journal of the American Medical Association, 1973
To the Editor.— The recent report by Greenblatt and Koch-Weser (225:40, 1973) provides an important example of the difficulty of attempting to evaluate retrospectively the incidence and nature of adverse reactions to a specific drug. Such programs as the Boston Collaborative Drug Surveillance Program are certainly commendable in their intent, but the ...
openaire   +3 more sources

Premenstrual Syndrome and Spironolactone

Australian and New Zealand Journal of Obstetrics and Gynaecology, 1991
Summary: A double blind placebo controlled randomized cross over study was conducted to assess the response to spironolactone by patients suffering from ‘Premenstrual Syndrome’. Somatic and neurophyschiatric symptoms were self‐assessed daily and a total score was calculated for each symptom for the 14 days prior to menstruation.
H. S. Radden, R. B. Burnet, E. G. Easterbrook, R. A. McKinnon   +3 more
openaire   +3 more sources

Usefulness of myocardial work measurement in the assessment of left ventricular systolic reserve response to spironolactone in heart failure with preserved ejection fraction.

European Heart Journal-Cardiovascular Imaging, 2019
AIMS Improvement in left ventricular (LV) systolic reserve, including exertional increase in global longitudinal strain (GLS), may contribute to the clinical benefit from therapeutic interventions in heart failure with preserved ejection fraction (HFpEF).
M. Przewłocka-Kosmala, T. Marwick, A. Mysiak, W. Kosowski, W. Kosmala   +4 more
semanticscholar   +1 more source

Spironolactone therapy in hypertrichosis

European Journal of Endocrinology, 1996
Darendeliler F, Baş F, Balaban S, Bundak R, Demirkol D, Saka N, Günöz H. Spironolactone therapy in hypertrichosis. Eur J Endocrinol 1996;135:604–8. ISSN 0804–4643 Although regarded as a benign condition, simple hypertrichosis may be very disturbing to a child cosmetically.
Rüveyde Bundak, Nurçin Saka, Demet Demirkol, Hülya Günöz, S Balaban, Feyza Darendeliler, Firdevs Bas   +6 more
openaire   +3 more sources